CLSN - CLSN STOCK NEWS

Celsion Corporation (NASDAQ: CLSN) announced the successful sale of approximately $1.5 million in unused New Jersey net operating losses (NOLs) for net cash proceeds of $1.4 million. This non-dilutive funding bolsters their balance sheet and extends their operating runway through 2024. With plans to sell an additional $3.5 million of NOLs, Celsion aims to support clinical development and operations. The company emphasizes participation in New Jersey's innovative funding programs, underscoring its commitment to advancing biotechnology in the state.

Celsion Corporation (NASDAQ: CLSN) announces a reverse stock split, consolidating its shares on a 1-for-15 basis, effective March 1, 2022. Post-split, approximately 5.8 million shares will be outstanding. The authorized shares and par value will remain unchanged. Holders of fractional shares will receive cash compensation. This move follows shareholder authorization and aims to maintain an efficient capital structure as the company advances its pipeline of cancer therapies, including DNA-based immunotherapy and nucleic acid vaccines.

Celsion Corporation (NASDAQ: CLSN) announced that the OVATION 2 Study is over 75% enrolled, with full enrollment expected by mid-2022. The study focuses on GEN-1, a gene-mediated immunotherapy for advanced ovarian cancer. Following a safety review, the Data Safety Monitoring Board recommended continuing the study, confirming that the treatment is well-tolerated without significant toxicities. Interim results show a 27% improvement in surgical resection rates for patients receiving GEN-1 compared to the control group. Celsion also plans to seek FDA Breakthrough Therapy Designation.

Celsion Corporation (NASDAQ: CLSN) has engaged BIOQUAL, Inc. for a non-human primate study of its DNA-based SARS-CoV-2 vaccine. This follows positive mouse study results showing safe immune responses, including neutralizing antibodies and T-cell reactions. Celsion’s novel vaccines are delivered via intramuscular injection, requiring no special equipment. The company has expanded its vaccine capabilities, including key hires and plasmid manufacturing capabilities, and aims to begin studies in Q2 2022, generating data to guide human clinical trials.

Celsion Corporation (NASDAQ: CLSN) has completed a registered direct offering, raising approximately $28.5 million by selling 50,000 shares each of Series A and Series B convertible redeemable preferred stock. The shares were sold at a price of $285 each, reflecting a 5% discount on their $300 stated value. A.G.P./Alliance Global Partners acted as the sole placement agent for this transaction. This offering was made under an effective shelf registration statement and aims to bolster Celsion's resources for advancing its cancer treatment portfolio, which includes DNA-based immunotherapies.

Celsion Corporation has entered into a securities purchase agreement with institutional investors to sell 50,000 shares of Series A and Series B convertible redeemable preferred stock at a total net proceeds of approximately $28.5 million. The Series A shares have an initial conversion price of $0.91, while Series B shares are priced at $1.00. Holders can convert their shares after the approval of a reverse stock split. The closing of the offerings is anticipated around January 13, 2022.

Celsion Corporation (NASDAQ: CLSN) announced that Dr. Khursheed Anwer will present the company's GEN-1 IL-12 immunotherapy program at the upcoming Cytokine-Based Cancer Immunotherapies Summit in Boston from November 30 to December 2, 2021. His presentation, scheduled for December 2 at 8:10 a.m. ET, will focus on a non-viral gene therapy approach for cancer treatment. Additionally, Dr. Anwer will partake in two panel discussions during the summit.

Positive results from GEN-1's Phase I study in advanced ovarian cancer have garnered interest from researchers.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company, reported a net loss of $5.4 million ($0.06 per share) for Q3 2021, an improvement from $8.1 million ($0.24 per share) in Q3 2020. Celsion's GEN-1 immunotherapy shows promise with an 80% R0 resection rate in patients, surpassing the control group by 24%. The company maintains a robust cash position of $60.6 million, expected to fund operations through 2024. The ongoing development of their DNA-based vaccine is poised to address COVID-19 variants. A conference call for detailed discussion will occur today at 11:00 a.m. ET.

Celsion Corporation (NASDAQ: CLSN), a clinical-stage biotech firm, will host a conference call on November 15, 2021, at 11:00 a.m. ET to discuss its financial results for Q3 2021 and provide updates on its product development. The company's lead product, GEN-1, is a DNA-based immunotherapy in Phase II trials for advanced ovarian cancer. Additionally, Celsion is developing PLACCINE, a synthetic vaccine technology, currently in preclinical studies. The call details and investor contact information are provided for interested parties.